Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Market concentration of new antibiotic sales

The Journal of Antibiotics volume 74, pages 421–423 (2021)Cite this article

Subjects

Abstract

We calculate the average sales of new antibiotics during their first 8 years on the market. The discounted net present value is only $240 m in total per antibiotic, well below costs of supplying these products. The reliance on the US for sales is striking: the US market accounts for 84% of sales during the first 8 years. These facts clarify the need for additional revenues, especially from other countries, to support incentives for the development of new antibiotics. Market entry rewards may be of particular value.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2

Notes

  1. Avibactam Ceftazidime, Ceftaroline Fosamil, Ceftobiprole modecaril, Ceftolozane, Dalbavancin, Delafloxacin, Meropenem vaborbactam, Oritavancin, Tedizolid, and Telvancin.

  2. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/206494Orig1s000ltr.pdf, https://www.ema.europa.eu/en/documents/assessment-report/zavicefta-epar-public-assessment-report_en.pdf, https://www.drugs.com/nda/dalvance_140401.html, https://www.ema.europa.eu/en/documents/assessment-report/xydalba-epar-public-assessment-report_en.pdf, https://www.ema.europa.eu/en/documents/assessment-report/xydalba-epar-public-assessment-report_en.pdf, all accessed 14 November 2020.

References

  1. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations. (Review on Antimicrobial Resistance, 2016); http://amrreview.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Last accessed 1 Nov 2020.

  2. Årdal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, et al. Antibiotic development — economic, regulatory and societal challenges. Nat Rev Microbiol. 2020;18:267–74. https://doi.org/10.1038/s41579-019-0293-3.

    Article  CAS  PubMed  Google Scholar 

  3. Outterson K. A shot in the arm for new antibiotics. Nat Biotechnol. 2019;37:1110–2. https://doi.org/10.1038/s41587-019-0279-8.

    Article  CAS  PubMed  Google Scholar 

  4. Simpkin VL, Renwick MJ, Kelly R, Mossialos E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot. 2017;70:1087.

    Article  CAS  Google Scholar 

  5. Krause K. Post-marketing commitments and Antimicrobial Susceptibility Test Development. ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Boston, MA; 2019. https://www.youtube.com/watch?v=XYpUoQnxnXE. Last accessed 1 Nov 2020.

  6. Lichtenstein C. Supply chain robustness, inventory build, and quality assurance. ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance. Boston, MA; 2019. https://www.youtube.com/watch?v=0VDDR4eY0o8. Last accessed 1 Nov 2020.

  7. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323:844–53.

    Article  Google Scholar 

  8. World Bank. World Bank Country and Lending Groups. 2020. https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups.

  9. Klein EY, Tseng KK, Pant S, Laxminarayan R. Tracking global trends in the effectiveness of antibiotic therapy using the Drug Resistance Index. BMJ Glob Health. 2019;4:1–7.

    Article  CAS  Google Scholar 

  10. Kang S-Y, Bai G, DiStefano MJ, Socal MP, Yehia F, Anderson GF. Comparative Approaches to Drug Pricing. Annu Rev Public Health. 2020;41:499–512. https://doi.org/10.1146/annurev-publhealth-040119-094305.

    Article  PubMed  Google Scholar 

  11. IQVIA Institute. Global medicine spending and usage trends: outlook to 2024. IQVIA Institute; 2020. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicine-spending-and-usage-trends.pdf. Last accessed 1 Nov 2020.

  12. Jacobs A. Crisis looms in antibiotics as drug makers go bankrupt. The New York Times, New York, NY, 2019.

  13. Gotham D, Beyer P, Moja L, van der Heijden M, Paulin S, Smith I. Reimbursement models to tackle market failures for antimicrobials: approaches taken in France, Germany, Sweden, the United Kingdom, and the United States. Health Policy (New York). 2020. http://www.sciencedirect.com/science/article/pii/S0168851020302980.

  14. Mahase E. UK launches subscription style model for antibiotics to encourage new development. BMJ. 2020;369. https://www.bmj.com/content/369/bmj.m2468.

  15. Morel CM, Lindahl O, Harbarth S, de Kraker MEA, Edwards S, Hollis A. Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus. J Antibiot 2020;73:421–8. https://doi.org/10.1038/s41429-020-0300-y.

    Article  CAS  Google Scholar 

Download references

Funding

Funding for this work comes from the Canadian Institute for Health Research (grant number pending), the Swiss National Fund (grant number 40AR40_180205/1), and the Swedish Research Council (grant number 2017-05973), coordinated via the Joint Programming Initiative on Antimicrobial Resistance, and the Major Innovation Fund program of the Ministry of Jobs, Economy and Innovation, Government of Alberta through the AMR – One Health Consortium. The funders have no involvement in the research itself.

Author information

Authors and Affiliations

  1. Department of Economics, University of Calgary, Calgary, AB, Canada

    Sakib Rahman & Aidan Hollis

  2. Department of Business Studies, Uppsala University, Kyrkogårdsgatan, Uppsala, Sweden

    Olof Lindahl & Chantal M. Morel

  3. University Hospital Bonn, Institute for Hygiene and Public Health, Bonn, Germany

    Chantal M. Morel

  4. University of Geneva Global Studies Institute, Geneva, Switzerland

    Chantal M. Morel

Authors
  1. Sakib Rahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olof Lindahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chantal M. Morel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aidan Hollis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aidan Hollis.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rahman, S., Lindahl, O., Morel, C.M. et al. Market concentration of new antibiotic sales. J Antibiot 74, 421–423 (2021). https://doi.org/10.1038/s41429-021-00414-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41429-021-00414-5

Search

Advanced search

Quick links